Fat but Fit: Fact or Myth?

High discontinuation rates as well as lower maintenance dosages of semaglutide and tirzepatide were among the independent predictors of lower real-world weight loss.

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

The novel triple fixed-dose combination of telmisartan, amlodipine and indapamide, is the first of its kind approved for initial treatment of hypertension.

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

Interim results from COURAGE trial suggest combining semaglutide with muscle-preserving antibodies significantly enhances fat loss while preserving lean mass in obesity treatment.

Research reveals that the quality of foods in low-carb and low-fat diets significantly impacts heart health, emphasizing whole, plant-based options.